I still don’t discount a Sarepta partnership for FDA route.
I can’t imagine Sarepta will pump $500m into more Gene Therapy investments / partnerships…
You would think both Sarepta and Pfizer would be taking notice of the proteomics data ANP released.
The message is: the P2B results were not a fluke - and the science behind the MoA is solid.
Who will blink first?
.
$36.8m raise, page-78
-
- There are more pages in this discussion • 142 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.8¢ |
Change
-0.002(2.50%) |
Mkt cap ! $70.32M | |||
| Open | High | Low | Value | Volume |
| 7.6¢ | 7.8¢ | 7.5¢ | $32.58K | 429.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 253224 | 7.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.0¢ | 253231 | 2 |
View Market Depth
| Last trade - 14.56pm 22/07/2024 (20 minute delay) ? |
| PER (ASX) Chart |